Genentech’s Xolair achieves co-primary and key secondary endpoints in chronic rhinosinusitis study

This article was originally published here

The company has revealed the positive topline data from two phase III multicentre studies assessing Xolair to treat adults with CRSwNP who have not adequately responded to intranasal

The post Genentech’s Xolair achieves co-primary and key secondary endpoints in chronic rhinosinusitis study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply